Remicade (infliximab) - J&J
Taltz (ixekizumab) - Eli Lilly
Bimzelx (bimekizumab-bkzx) - UCB
Cimzia (certolizumab pegol) - Astellas, UCB
Humira (adalimumab) - AbbVie
Tremfya (guselkumab) - J&J
Ilumya (tildrakizumab-asmn) - Sun Pharma, Almirall
Cosentyx (secukinumab) - Novartis
Stelara (ustekinumab) - J&J
Skyrizi (risankizumab-rzaa) - AbbVie, Boehringer Ingelheim
Siliq (brodalumab) - Bausch Health
Enbrel (etanercept) - Pfizer, Amgen
Real-World Strategies for Biologic Dose Escalation and Reduction in Psoriasis and Psoriatic Arthritis: A Systematic Review. (PubMed, J Cutan Med Surg) - Sep 30, 2026 - "Dose adjustments are common but inconsistently defined, highlighting the need for standardized definitions and clinical guidance." 
Journal • Real-world evidence • Dermatology • Immunology • Inflammatory Arthritis • Oncology • Psoriasis • Psoriatic Arthritis • Rheumatology • Seronegative Spondyloarthropathies • IL12A • IL17A • IL23A
http://www.ncbi.nlm.nih.gov/pubmed/42806636
 
Eleonora Bongiovanni; Isotta Giunipero di Corteranzo; Luca Mastorino; Michela Ortoncelli; Orsola Crespi; Pietro Quaglino; Simone Ribero; Umberto Santaniello
 
Sep 30, 2026
 
Prev Next